false
Catalog
Multiprofessional Critical Care Review: Adult (202 ...
6: Inotropes and Vasoactive Agents in Cardiogenic ...
6: Inotropes and Vasoactive Agents in Cardiogenic Shock (Steven M. Hollenberg, MD, FACC, FAHA, FCCP)
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this video, Dr. Steve Hollenberg discusses the use of inotropes and vasoactive agents in the management of cardiogenic shock. He begins by defining shock as inadequate perfusion and oxidation of cells, which leads to cellular and organ dysfunction and damage. Cardiogenic shock occurs when this perfusion defect results from cardiac dysfunction. Dr. Hollenberg emphasizes the importance of diagnosing and treating cardiogenic shock promptly, as it is a hemodynamic disease that can lead to mortality if left untreated. He provides an overview of the diagnostic approach, which includes a directed history and physical examination, EKG, labs, and echocardiography.<br /><br />Dr. Hollenberg highlights the significance of early coronary reperfusion in cardiogenic shock caused by an acute coronary syndrome. He discusses the role of pulmonary artery catheterization in hemodynamic assessment and management of cardiogenic shock. Dr. Hollenberg explains the different vasopressors and inotropes that can be used to support perfusion in cardiogenic shock, including norepinephrine, dopamine, epinephrine, and phenylephrine. He also mentions the use of vasopressin as an alternative vasoconstrictive agent. Dr. Hollenberg describes the complications associated with vasoactive therapies, such as tachyarrhythmias, myocardial ischemia, impaired splanchnic circulation, and immunosuppression.<br /><br />In terms of inotropic agents, Dr. Hollenberg discusses the use of dobutamine, a selective beta-1 adrenergic agonist, and milrinone, a bipyridine phosphodiesterase inhibitor. He mentions the DO-RE-MI trial, which compared milrinone with dobutamine in the treatment of cardiogenic shock and found no significant difference in outcomes. Dr. Hollenberg concludes by emphasizing the importance of individualized management based on the patient's hemodynamic profile and the need for ongoing assessment and adjustment of therapy to achieve adequate perfusion.
Keywords
cardiogenic shock
diagnosis
treatment
hemodynamic assessment
vasopressors
inotropic agents
individualized management
Society of Critical Care Medicine
500 Midway Drive
Mount Prospect,
IL 60056 USA
Phone: +1 847 827-6888
Fax: +1 847 439-7226
Email:
support@sccm.org
Contact Us
About SCCM
Newsroom
Advertising & Sponsorship
DONATE
MySCCM
LearnICU
Patients & Families
Surviving Sepsis Campaign
Critical Care Societies Collaborative
GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. |
Privacy Statement
|
Terms & Conditions
The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.
×
Please select your language
1
English